Home
Explore NIH Technologies
Explore work by over 1,500 NIH researchers | Available for Licensing & Collaboration
News
The NIH Technology Transfer Program was honored with its record 7th “Deal of Distinction Award” at the 2025 Licensing Executives Society Annual Meeting. This award was given to NIH and its licensee Bavarian Nordic for the deal that led to the new chikungunya virus vaccine Vimkunya ®. Vimkunya
NIH inventors have developed the first pharmacologic option for developmental stuttering, which is currently only managed by speech therapy, but addresses a $3 billion underserved global market. This technology uses small-molecule iron chelators – drugs that bind and remove excess iron – for the
Broad access to the fruits of NIH’s investments—whether in the form of data, results, or products—drives innovation. To advance this aim, NIH is launching a new policy to improve access to medical products developed from NIH-owned inventions. This policy emphasizes the importance of proactive
Meet with NIH Technology Transfer experts at the BioHealth Capital Region Forum to discuss how companies, entrepreneurs, and other buy-side stakeholders can partner with the NIH to bolster their pipeline. We can discuss partnership models beyond academic/basic research and SBIRs, success stories and
Explore Featured Research
Get updates on the latest and most exciting research coming out of NIH...
Explore Featured Products
Novel and interesting products coming to market through NIH inventions and partnerships...